Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

aTYR PHARMA (ATYR) Change in Receivables (2019 - 2025)

Historic Change in Receivables for aTYR PHARMA (ATYR) over the last 7 years, with Q3 2025 value amounting to $544000.0.

  • aTYR PHARMA's Change in Receivables rose 16798.03% to $544000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was -$789000.0, marking a year-over-year decrease of 62251.66%. This contributed to the annual value of -$402000.0 for FY2024, which is 9556.0% up from last year.
  • Per aTYR PHARMA's latest filing, its Change in Receivables stood at $544000.0 for Q3 2025, which was up 16798.03% from -$490000.0 recorded in Q2 2025.
  • Over the past 5 years, aTYR PHARMA's Change in Receivables peaked at $12.0 million during Q4 2022, and registered a low of -$9.9 million during Q1 2023.
  • In the last 5 years, aTYR PHARMA's Change in Receivables had a median value of -$32500.0 in 2022 and averaged $9388.9.
  • Its Change in Receivables has fluctuated over the past 5 years, first surged by 381928.1% in 2022, then crashed by 10971111.11% in 2023.
  • Quarter analysis of 5 years shows aTYR PHARMA's Change in Receivables stood at $306000.0 in 2021, then surged by 3819.28% to $12.0 million in 2022, then crashed by 96.18% to $458000.0 in 2023, then tumbled by 120.74% to -$95000.0 in 2024, then skyrocketed by 672.63% to $544000.0 in 2025.
  • Its Change in Receivables was $544000.0 in Q3 2025, compared to -$490000.0 in Q2 2025 and -$748000.0 in Q1 2025.